A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Trial Profile

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LARIAT
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 02 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 May 2018.
    • 22 Mar 2018 Primary endpoint (Change from baseline in 6-Minute Walk Distance (6MWD) in patients with pulmonary hypertension (PH) associated with interstitial lung diseases (idiopathic pulmonary fibrosis or sarcoidosis)) has been met, according to top-line results presented in a Reata Pharmaceuticals media release.
    • 22 Mar 2018 Top-Line results (n=33) for the treatment of pulmonary hypertension associated with interstitial lung diseases (idiopathic pulmonary fibrosis and Sarcoidosis), presented in a Reata Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top